Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase 2 KEYNOTE-158 study.

5522Background: The KEYNOTE-158 study (NCT02628067) is a phase II basket study investigating the antitumor activity of pembrolizumab, an IgG4 anti-PD-1 monoclonal antibody, in 11 cancer types. An u...